Our Management Team
Edward Breitschwerdt, DVM
Chief Scientific Officer
Dr. Breitschwerdt is an internist and professor of medicine and infectious diseases at North Carolina State University’s College of Veterinary Medicine. He is a co-director of the Vector Borne Disease Diagnostic Laboratory, which has been testing animals for vector-borne infections, including Bartonella, since 1984. With over 200 peer-reviewed publications, Dr. Breitschwerdt is an internationally recognized leader in Bartonella research, diagnosis and treatment. He has been consulted widely about an array of infectious diseases by many leading companies in the veterinary diagnostics, therapeutic and vaccine industries. Dr. Breitschwerdt’s research at the NCSU Intracellular Pathogens Research Laboratory has produced significant research findings concerning the medical importance of Bartonella and other emerging infectious disease pathogens.
Amanda B. Elam, PhD
President/Chief Executive Officer
Dr. Elam holds a doctorate in Sociology from the University of North Carolina at Chapel Hill and has published extensively on the topic of business start-up. Her doctoral research on entrepreneurship has been recognized by the Academy of Management for innovative thought leadership. In addition to leading the Galaxy team, Dr. Elam directs research projects on entrepreneurship and women’s leadership at Babson College’s Center for Women’s Entrepreneurial Leadership. After graduating from chief cook and bottle washer, Dr. Elam now focuses on corporate strategy and business development activities at Galaxy.
Ricardo Maggi, PhD
Chief Technical Officer
Dr. Maggi holds a doctorate in molecular biology and is an Associate Professor of Medical Microbiology at the College of Veterinary Medicine at North Carolina State University, where he directs research at the Intracellular Pathogens Research Laboratory. Dr. Maggi brings a diverse background in molecular biology and bacterial culture to Galaxy. He played an integral role in the development of our proprietary diagnostic technology, BAPGM, and leads molecular assay development and bacterial culture for the Galaxy R&D team.
Jennifer Miller, PhD
Director of Research and Development
Dr. Miller holds a doctorate in microbiology and brings an exceptional and diverse background in microbiology research and education to Galaxy. With over 20 years of experience with vector-borne and zoonotic pathogens, including the Lyme disease spirochete Borrelia burgdorferi, and Leptospira interrogans, the causative agent of leptospirosis, Dr. Miller leads clinical assay development and the diagnostic test portfolio at Galaxy. Her experience as a professor of microbiology at North Carolina State University, where she developed her own research program and laboratory focused on in vitro and murine studies of vector-borne diseases, provides significant insights into optimal research designs and grant proposal strategy in support of Galaxy Contract Research Services.
B. Robert Mozayeni, MD
Dr. Mozayeni is a rheumatologist with graduate and post-graduate physician-scientist training from Albany Medical College, Yale University, Howard Hughes Medical Institute and the National Institutes of Health (NCI, NHLBI and NIAMS). He is presently in private practice in Bethesda, Maryland, where he specializes in chronic inflammatory diseases having rheumatic and neurovascular manifestations. Dr. Mozayeni is the founder and Executive Director of the Translational Medicine Group, where he has developed and commercialized software that supports data-driven methods to accelerate the evaluation and improvement of patient-centered care pathways. Under an ongoing research collaboration with Dr. Breitschwerdt, Dr. Mozayeni maintains an observational clinical evaluation of the significance of Bartonella infection in a cohort of several hundred human patients with otherwise unexplained chronic conditions. Clinical correlations between Bartonella species and various conditions are being determined as part of ongoing research that continues to redefine diagnostic and therapeutic options as dictated by clinical experience.
Natalie Cherry Smith, PhD
Dr. Smith holds a doctorate in biomedical sciences from North Carolina State University, where she worked extensively with the BAPGM technology as part of the NCSU Bartonella research team led by Dr. Breitschwerdt. Dr. Smith’s research has focused primarily on clinical and experimental infection studies of bartonellosis in dogs and horses, with additional research on the prevalence of a range of vector-borne infections in dogs and people. Dr. Smith helped launch human health testing in 2012 and now directs laboratory operations and quality control at Galaxy.